US OptionsDetailed Quotes
SLRN250516P2500
- 0.50
- 0.000.00%
15min DelayTrading Apr 8 12:17 ET
0.00High0.00Low
0.00Open0.50Pre Close0 Volume82 Open Interest2.50Strike Price0.00Turnover222.90%IV16.84%PremiumMay 16, 2025Expiry Date0.10Intrinsic Value100Multiplier16DDays to Expiry0.41Extrinsic Value100Contract SizeAmericanOptions Type-0.4386Delta0.3506Gamma4.81Leverage Ratio-0.0139Theta-0.0006Rho-2.11Eff Leverage0.0020Vega
Acelyrin Stock Discussion
$737 Million Deal Reshapes Immunology Sector: Inside Alumis and ACELYRIN's Strategic Merger Revolution
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Friday, 4th April at 4:34 pm
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet
Boards unanimously recommend stockholders vote "FOR" the merger
Transaction expected to be completed in second quarter of 2025
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ: ALMS), a clinical-stage biopharmaceuti...
WSJ· 4 mins ago
Acelyrin said its board approved adopting a limited-duration shareholders' rights plan in response to Tang Capital Partners' accumulation of a stake in the company.
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will become exercisable...
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment?
share buyback at $3, shorts only touched this a tiny bit. I think shorts would only touch this once it got over $3.
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
$Acelyrin (SLRN.US)$
has options
nfa
$Acelyrin (SLRN.US)$
has options
nfa
No comment yet